Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.Financial_Report.xls
10-K - Arch Therapeutics, Inc.g6510.txt
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R26.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R24.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R25.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R23.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R27.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R13.htm
EX-32.1 - Arch Therapeutics, Inc.ex32-1.txt
EX-31.1 - Arch Therapeutics, Inc.ex31-1.txt
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R20.htm
v2.4.0.6
Note 1 - Overview and Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies)
12 Months Ended
Sep. 30, 2012
Policies  
Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.